Dec 06, 2025 • MarketBeat
NEUTRAL
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock
MannKind CEO Michael Castagna sold 107,920 shares of the company's stock on December 2nd at an average price of $5.57, totaling over $600,000. This sale reduced his stake by 4.13%. The stock traded up 2.1% after the news, and analysts have a consensus "Moderate Buy" rating with a price target of $10.06.
Dec 06, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector
MannKind recently saw its supplemental FDA filing for the FUROSCIX ReadyFlow Autoinjector accepted, enhancing its pipeline. Although the stock has experienced recent volatility with a negative year-to-date return, its 5-year total shareholder return remains strong at 96.90%. The company's valuation is deemed 39.2% undervalued, with a fair value target near $9.39, supported by a $500M financing from Blackstone to accelerate commercialization and pipeline development.
Dec 05, 2025 • Investing.com South Africa
NEUTRAL
Mannkind EVP Thomson sells $823k in shares By Investing.com
David Thomson, EVP at Mannkind Corp, sold 147,780 shares of common stock for $823,134 on December 2, 2025, while also exercising options to acquire an equal number of shares. This sale was conducted under a pre-arranged trading plan.
Dec 05, 2025 • Investing.com
NEUTRAL
Mannkind CEO Castagna sells $601k in shares
Mannkind Corp (NASDAQ:MNKD) CEO Michael Castagna sold 107,920 shares of company stock for over $601,000 on December 2, 2025, after exercising options for an equal number of shares. The biopharmaceutical company, valued at $1.76 billion, has a "GREAT" financial health rating and analysts maintain a strong "Buy" consensus. Recent developments include FDA acceptance for a new device application and the discontinuation of a Phase 3 clinical trial.
Dec 02, 2025 • Stock Titan
BULLISH
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow
MannKind announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for FUROSCIX ReadyFlow Autoinjector, which is designed to treat edema in adults with chronic heart failure or chronic kidney disease. The sNDA has been assigned a PDUFA target action date of July 26, 2026. This potential approval could offer a rapid, at-home treatment option, reducing administration time from five hours to under 10 seconds.
Dec 02, 2025 • Diagnostic and Interventional Cardiology
BULLISH
FDA Reviewing 10-Second Treatment for Edema in Heart Failure
The FDA has accepted MannKind's Supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, a device designed to deliver a subcutaneous furosemide injection in less than 10 seconds. This autoinjector aims to treat edema in adults with chronic heart failure or chronic kidney disease, offering a faster alternative to the current on-body infusor and potentially reducing hospital admissions. The PDUFA target action date is July 26, 2026.